Dr. Litton on a Study of Neoadjuvant Talazoparib for Patients With BRCA-Mutated TNBC

(2:2)

Neoadjuvant talazoparib active in BRCA-mutated early breast cancer | Jennifer Litton

(4:56)

Neoadjuvant Talazoparib for BRCA 1/2 Mutated Triple Negative Breast Cancer

(6:1econd)

What is Neoadjuvant Therapy? | Dana-Farber Cancer Institute

(3:20)

Talazoparib plus enzalutamide shows improvement in PFS over SOC in first-line HRR mCRPC

(5:1econd)

Dr. Yardley Discusses Data With Talazoparib in Breast Cancer

(1:50)

Exploring Neoadjuvant Therapy for Breast Cancer: What You Need to Know

(10:5)

Sequencing in BRCA-Positive TNBC Patients

(3:3)

Neoadjuvant Durvalumab Shows Benefit in Triple-Negative Breast Cancer

(1:8)

Advances in PARP inhibitor use for metastatic breast cancer

(3:4)

Dr. Agarwal on the Safety Profile of Enzalutamide/Talazoparib in mCRPC

(1:2)

Rates of pathologic complete response after neoadjuvant datopotamab deruxtecan in neoadjuvant br...

(4:7)

KEYNOTE 522: pembrolizumab as neoadjuvant treatment for early TNBC

(4:20)

Escalation and descalation in neoadjuvant time to treatment of TNBC

(3:18)

Adherence \u0026 outcomes of neoadjuvant immunotherapy in resectable NSCLC

(58)

Pathologic complete response rates improved with the neoadjuvant and adjuvant treatment of pembr...

(7:15)

Neoadjuvant Treatment in Triple-Negative Breast Cancer

(12:47)

Adjuvant/Neoadjuvant Therapy for Breast Cancer: Updates and Molecular Predictors of Benefit

(38:22)

Neoadjuvant chemotherapy utilization and perioperative morbidity

(3:51)

Sara M. Tolaney on Neoadjuvant Treatment Considerations for Triple-Negative Breast Cancer

(1:9)